Keros Therapeutics, Inc. KROS
Keros Therapeutics, Inc. (Nasdaq: KROS) is a CNS/neurology/psychiatry drug developer. Its lead program, rinvatercept (KER-065), is in Phase 2 for Duchenne muscular dystrophy (DMD); ALS planned. Its next catalyst on record is rinvatercept (KER-065): Engage regulators on design of Phase 2 trial in ALS (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: rinvatercept (KER-065) — Engage regulators on design of Phase 2 trial in ALS (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| rinvatercept (KER-065) | Duchenne muscular dystrophy | protein/peptide | Phase 2 |
| rinvatercept (KER-065) | Amyotrophic lateral sclerosis | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.